A Phase 2 interventional study of rMenB+OMV NZ and combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine in Meningococcal Infections, sponsored by Novartis Vaccines. Completed at 60 sites in 6 countries. Open to participants aged 55 Days to 89 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-23.
Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing 4CMenB vaccine in Meningococcal Infections — 1 open to participants now, 2 under way, none of them phase 3. 4CMenB vaccine · Meningococcal Infections.
Among the 21 studies testing 4CMenB vaccine in Meningococcal Infections, this one is the 3rd largest by enrollment, is one of 2 that started in 2008, is one of 7 in phase 2, and was the 4th registered.
243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.
Browse Meningococcal Infections studies →1 of the 21 studies testing 4CMenB vaccine in Meningococcal Infections is open now, in 1 country. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
4CMenB vaccine: first FDA approval 2014 (Trumenba). What it is approved for, and how studies give it, is on its page →
Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 55 Days to 89 Days · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 9 · Phase 4 4
First in 2006; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,885 is above the median of 456 across 214 interventional studies indexed under Meningococcal Infections.
Median enrollment 508 across the 21 interventional studies. Of the 19 that completed or were terminated, 15 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 21 have an industry lead sponsor. The 7 most frequent:
This study is registered under Novartis Vaccines, one of the names counted as Novartis. Under that name alone:
Novartis Vaccines is the lead sponsor of 165 studies on the registry; none are open to participants now.
60 studies in Meningococcal Infections by Novartis: none open now, none under way, none of them phase 3. Of 59 finished, 48 (81%) have results posted.
Among the 60 studies in Meningococcal Infections by Novartis, this one is the 8th largest by enrollment of the 57 interventional ones that give a count, is one of 7 that started in 2008, is one of 21 in phase 2, and was the 26th registered.
Novartis’s Meningococcal Infections studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing 4CMenB vaccine in Meningococcal Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 60 in Meningococcal Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary :1.To demonstrate a sufficient immune response of rMenB+OMV NZ, when given concomitantly with routine infant vaccines to healthy infants at 2, 4 and 6 and 2, 3 and 4 months of age, as measured by percentage of subjects with serum bactericidal activity (SBA) titer ≥1:5, at 1 month after the third vaccination Secondary :To demonstrate that immunogenicity of routine infant vaccines, when given concomitantly with rMenB+OMV NZ to healthy infants at 2, 3 and 4 months of age, was non-inferior to that of routine infant vaccines given without rMenB+OMV NZ. 2. To demonstrate that the immunogenicity of rMenB+OMV NZ when given concomitantly with routine infant vaccines was non-inferior to that of rMenB+OMV NZ given without routine infant vaccines at 2, 4 and 6 months of age. 3. To assess prevalence of meningococcal B antibodies over the study period by evaluation of SBA, at baseline and at 1 month after third vaccination, in subjects- received routine infant vaccine without rMenB+OMV NZ.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in this group received rMenB+OMV NZ vaccine at 2, 4, and 6 months of age, administered concomitantly with routine infant vaccinations.
Biological: rMenB+OMV NZ · Biological: combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine · Biological: Pneumococcal vaccine
Subjects in this group received rMenB+OMV NZ vaccine at at 2, 4, and 6 months of age; routine infant vaccinations were administered at 3, 5 and 7 months of age.
Biological: rMenB+OMV NZ · Biological: combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine · Biological: Pneumococcal vaccine
Subjects in this group received rMenB+OMV NZ vaccine at 2, 3, 4 months of age, administered concomitantly with routine infant vaccinations.
Biological: rMenB+OMV NZ · Biological: combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine · Biological: Pneumococcal vaccine
Subjects in this group received routine infant vaccines administered at 2, 3 and 4 months of age.
Biological: combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine · Biological: Pneumococcal vaccine
Drug page: 4CMenB vaccine
Also known as: Infanrix Hexa
Also known as: Prevenar
Percentage of Subjects With Serum Bactericidal Activity ≥1:5 After Receiving Three Doses of rMenB+OMV NZ Vaccine
The percentage of subjects with serum bactericidal activity(hSBA)titer ≥1:5 after receiving three doses of rMenB+OMV NZ vaccine were evaluated to demonstrate sufficient immune response following rMenB+OMV NZ vaccination, when given concomitantly with routine infant vaccines to healthy infants. The serum bactericidal antibodies directed against serogroup B meningococci, are measured by human complement Serum Bactericidal Assay (hSBA). The immune response was considered sufficient for groups B+R246 and B+R234 if the lower limit of the 2-sided 95% confidence interval was ≥ 70% for all three strains.
Time frame: One month after third Men B vaccination
Safety and Tolerability of 3 Doses of rMenB - Concomitantly With Routine Infant Vaccines at 2, 4 and 6 Months of Age - Concomitantly With Routine Vaccines at 2, 3 and 4 Months of Age - Alone at 2, 4 and 6 Months of Age
Safety and Tolerability of 3 Doses of rMenB was assessed in terms of the number of subjects who reported solicited local and systemic adverse events when administered concomitantly with routine infant vaccines at 2,4,6 months of age (B+R246) to when rMenB+OMV NZ and routine vaccines were administered separately (group B246_R357).
Time frame: 10 months (groups 1 and 2); 8 months (groups 3 and 4)
Non-inferiority of Immune Response to rMenB+OMV NZ Vaccination When Administered Concomitantly With Routine Infant Vaccines at 2,4,6 Months of Age
The non-inferiority of immune response to rMenB+OMV NZ vaccination when administered concomitantly with routine infant vaccines at 2,4,6 months of age(B+R246) to when rMenB+OMV NZ and routine vaccines were administered separately (group B246_R357)was assessed in terms of percentage of subjects With hSBA≥ 1:5.
Time frame: One month after 3rd Men B vaccination
Non-inferiority of Immune Response to Diphtheria and Tetanus Antigens When Routine Vaccines Are Administered Concomitantly With rMen+OMV NZ Vaccine
Non-inferiority of immune response to routine vaccine antigens when routine vaccines were administered concomitantly with rMenB+OMV NZ vaccine \[group B+R234\] to when only routine vaccines were given \[Group R234\] were assessed in terms of percentage of subjects with antibody concentrations ≥0.1 IU/mL against Diphtheria and Tetanus antigens as measured by enzyme-linked immunosorbent assay.
Time frame: One month after 3rd vaccination
Geometric Mean Titers Against Neisseria Meningitidis Serogroup B, When rMenB+OMV NZ Vaccine is Administered Concomitantly With Routine Infant Vaccines.
The hSBA antibody titers when rMenB+OMV NZ vaccine is administered concomitantly with routine infant vaccines to when rMenB+OMV NZ vaccine and routine vaccines were given separately are reported in terms of vaccine-group-specific geometric mean titers.
Time frame: One month after third Men B vaccination
Geometric Mean Ratio of hSBA Titers, When rMenB+OMV NZ Vaccine is Administered Concomitantly With Routine Infant Vaccines.
The geometric mean ratio(GMR) of GMTs at 1 month after 3rd rMenB+OMV NZ vaccination to prevaccination GMTs, when rMenB+OMV NZ was administered concomitantly with routine infant vaccines to when rMenB+OMV NZ vaccine and routine vaccines were given separately.
Time frame: one month after third Men B vaccination
Percentage of Subjects With hSBA ≥1:8 After Receiving Three Doses of rMenB+OMV NZ Vaccine.
The percentage of subjects with hSBA titers ≥1:8, following rMenB+OMV NZ vaccination when given concomitantly with routine infant vaccines to when rMenB+OMV NZ and routine vaccines were given separately.
Time frame: One month after third Men B vaccination
Percentage of Subjects With 4-fold Rise in hSBA Titers, When rMenB+OMV NZ Vaccine is Administered Concomitantly With Routine Infant Vaccines.
The percentage of subjects with 4-fold rise in hSBA titers at 1 month after 3rd rMenB+OMV NZ vaccination from baseline, when rMenB+OMV NZ was administered concomitantly with routine infant vaccines to when rMenB+OMV NZ vaccine and routine vaccines were given separately.
Time frame: One month after third Men B vaccination
Non-inferiority of Immune Response to Acellular Pertussis Antigens When Routine Vaccines Are Administered Concomitantly With rMen+OMV NZ Vaccine.
Non-inferiority of immune response to routine vaccine antigens when routine vaccines were administered concomitantly with rMenB+OMV NZ vaccine \[group B+R234\] to when only routine vaccines were given \[Group R234\] were assessed in terms of percentage of subjects achieving seroconversion for pertussis antigens - Filamentous Hemagglutinin (FHA), Pertactin and Pertussis Toxoid (PT) at 1 month after 3rd vaccination versus baseline. Seroconversion was defined as a 4-fold increase for each pertussis antigen or in those initially seropositive, persistence of the pre-vaccination antibody concentration at least at the same antibody concentration as before vaccination, taking into account the decay of maternal antibodies.
Time frame: 1 month after 3rd vaccination
Subjects were recruited from 4 centers in UK, 5 centers in Italy, 16 centers in Spain, 6 centers in Belgium, 25 centers in Germany and 4 centers in Czech Republic
| Milestone | B+R246 | B246_R357 | B+R234 | R234 |
|---|---|---|---|---|
| Started | 627 | 628 | 318 | 312 |
| Completed | 597 | 592 | 308 | 302 |
| Not completed | 30 | 36 | 10 | 10 |
| Withdrew: Adverse event | 4 | 7 | 2 | 0 |
| Withdrew: Withdrawal by subject | 12 | 15 | 3 | 7 |
| Withdrew: Lost to follow-up | 7 | 9 | 3 | 3 |
| Withdrew: Protocol violation | 4 | 3 | 1 | 0 |
| Withdrew: Inappropriate enrollment | 0 | 2 | 0 | 0 |
| Withdrew: Administrative reason | 3 | 0 | 1 | 0 |
The percentage of subjects with serum bactericidal activity(hSBA)titer ≥1:5 after receiving three doses of rMenB+OMV NZ vaccine were evaluated to demonstrate sufficient immune response following rMenB+OMV NZ vaccination, when given concomitantly with routine infant vaccines to healthy infants. The serum bactericidal antibodies directed against serogroup B meningococci, are measured by human complement Serum Bactericidal Assay (hSBA). The immune response was considered sufficient for groups B+R246 and B+R234 if the lower limit of the 2-sided 95% confidence interval was ≥ 70% for all three strains.
| Percentages of subjects | B+R246 | B246_R357 | B+R234 | R234 |
|---|---|---|---|---|
| Baseline (44/76-SL strain)N=587,589,300,291 | 9 (6 to 11) | 7 (5 to 9) | 6 (4 to 10) | 6 (4 to 10) |
| Post vaccination (44/76-SL)N=550,561,283,265 | 99 (98 to 100) | 99 (98 to 100) | 99 (97 to 100) | 4 (2 to 7) |
| Baseline (5/99 strain)N=580,577,294,289 | 5 (4 to 8) | 7 (5 to 9) | 5 (3 to 8) | 6 (3 to 9) |
| Post vaccination (5/99 strain)N=551,554,285,245 | 99 (98 to 100) | 99 (98 to 100) | 100 (99 to 100) | 5 (3 to 8) |
| Baseline(NZ98/254 strain)N=582,583,298,292 | 3 (2 to 5) | 1 (0 to 2) | 2 (1 to 4) | 1 (0.083 to 2) |
| Post vaccination(NZ98/254 strain)N=555,559,284,269 | 79 (75 to 82) | 87 (84 to 89) | 81 (76 to 85) | 4 (2 to 8) |
Safety and Tolerability of 3 Doses of rMenB was assessed in terms of the number of subjects who reported solicited local and systemic adverse events when administered concomitantly with routine infant vaccines at 2,4,6 months of age (B+R246) to when rMenB+OMV NZ and routine vaccines were administered separately (group B246_R357).
| Number of subjects | B+R246 | B246_R357 | B+R234 | R234 |
|---|---|---|---|---|
| Tenderness (N=624,626,318,311) | 529 | 491 | 265 | 0 |
| Erythema (N=624,626,318,311) | 506 | 516 | 257 | 0 |
| Induration (N=624,626,318,311) | 447 | 465 | 230 | 0 |
| Swelling (N=624,626,318,311) | 290 | 324 | 149 | 0 |
| Change in Eating Habits (N=624,626,318,311) | 470 | 473 | 249 | 159 |
| Sleepiness (N=624,626,318,311) | 523 | 525 | 282 | 224 |
| Vomiting (N=624,626,318,311) | 193 | 234 | 97 | 83 |
| Diarrhea (N=624,626,318,311) | 284 | 327 | 138 | 113 |
| Irritability (N=624,626,318,311) | 543 | 527 | 289 | 220 |
| Unusual Crying (N=624,626,318,311) | 526 | 515 | 268 | 186 |
| Rash (N=624,626,318,311) | 84 | 130 | 42 | 39 |
| Fever (≥38.0 C° %) ((N=624,627,318,311) | 501 | 447 | 243 | 160 |
The non-inferiority of immune response to rMenB+OMV NZ vaccination when administered concomitantly with routine infant vaccines at 2,4,6 months of age(B+R246) to when rMenB+OMV NZ and routine vaccines were administered separately (group B246_R357)was assessed in terms of percentage of subjects With hSBA≥ 1:5.
| Percentages of subjects | B+R246 | B246_R357 |
|---|---|---|
| Baseline(44/76-SL strain) | 8 (6 to 11) | 7 (5 to 9) |
| 1 month post 3rd vaccination(44/76-SL)N=525,534 | 100 (99 to 100) | 100 (99 to 100) |
| Baseline(5/99 strain)N=511,537 | 6 (4 to 8) | 7 (5 to 9) |
| 1 month post 3rd vaccination(5/99strain)N=527,529 | 100 (99 to 100) | 99 (98 to 100) |
| Baseline(NZ98/254 strain)N=554,543 | 3 (2 to 5) | 1 (0 to 2) |
| 1 month post 3rd vaccination(NZ98/254 )N=530,534 | 79 (76 to 83) | 87 (84 to 90) |
Non-inferiority of immune response to routine vaccine antigens when routine vaccines were administered concomitantly with rMenB+OMV NZ vaccine \[group B+R234\] to when only routine vaccines were given \[Group R234\] were assessed in terms of percentage of subjects with antibody concentrations ≥0.1 IU/mL against Diphtheria and Tetanus antigens as measured by enzyme-linked immunosorbent assay.
| Percentages of subjects | B+R234 | R234 |
|---|---|---|
| Baseline (Diphtheria) | 25 (20 to 30) | 21 (16 to 26) |
| 1 month after 3rd vaccination(Diphtheria)N=261,232 | 100 (99 to 100) | 100 (98 to 100) |
| Baseline (Tetanus) | 81 (76 to 86) | 86 (81 to 90) |
| 1 month after 3rd vaccination (Tetanus)N=261,232 | 100 (99 to 100) | 100 (98 to 100) |
The hSBA antibody titers when rMenB+OMV NZ vaccine is administered concomitantly with routine infant vaccines to when rMenB+OMV NZ vaccine and routine vaccines were given separately are reported in terms of vaccine-group-specific geometric mean titers.
| Titers | B+R246 | B246_R357 | B+R234 | R234 |
|---|---|---|---|---|
| Baseline (44/76-SL strain) N=556,548,285,277 | 1.49 (1.4 to 1.59) | 1.36 (1.28 to 1.46) | 1.34 (1.23 to 1.46) | 1.28 (1.19 to 1.37) |
| post vaccination (44/76-SL) N=525,534,273,253 | 86 (80 to 92) | 113 (105 to 121) | 82 (75 to 91) | 1.16 (1.09 to 1.24) |
| Baseline (5/99 strain) N=551,537,280,275 | 1.3 (1.21 to 1.39) | 1.28 (1.2 to 1.37) | 1.19 (1.09 to 1.3) | 1.24 (1.15 to 1.33) |
| post vaccination (5/99 strain)N=527,529,275,236 | 537 (494 to 584) | 699 (643 to 759) | 325 (292 to 362) | 1.25 (1.08 to 1.45) |
| Baseline (NZ98/254 strain)N=554,543,283,278 | 1.13 (1.08 to 1.18) | 1.08 (1.04 to 1.13) | 1.06 (1 to 1.12) | 1.07 (1.03 to 1.1) |
| post vaccination (NZ98/254 strain)N=30,534,274,257 | 12 (11 to 14) | 18 (16 to 20) | 11 (9.14 to 12) | 1.11 (1.04 to 1.19) |
The geometric mean ratio(GMR) of GMTs at 1 month after 3rd rMenB+OMV NZ vaccination to prevaccination GMTs, when rMenB+OMV NZ was administered concomitantly with routine infant vaccines to when rMenB+OMV NZ vaccine and routine vaccines were given separately.
| Ratio | B+R246 | B246_R357 | B+R234 | R234 |
|---|---|---|---|---|
| 44/76-SL strain (N=501,507,262,236) | 58 (52 to 64) | 83 (74 to 92) | 61 (53 to 70) | 0.91 (0.83 to 1) |
| 5/99 strain (N=497,494,257,217) | 430 (379 to 487) | 553 (489 to 625) | 271 (231 to 318) | 1.03 (0.86 to 1.22) |
| NZ98/254 strain (N=504,503,258,238) | 11 (9.28 to 12) | 16 (14 to 19) | 10 (8.52 to 12) | 1.05 (0.97 to 1.14) |
The percentage of subjects with hSBA titers ≥1:8, following rMenB+OMV NZ vaccination when given concomitantly with routine infant vaccines to when rMenB+OMV NZ and routine vaccines were given separately.
| Percentages of subjects | B+R246 | B246_R357 | B+R234 | R234 |
|---|---|---|---|---|
| Baseline (44/76-SL strain)N=556,548,285,277 | 4 (3 to 6) | 3 (2 to 5) | 4 (2 to 7) | 2 (1 to 5) |
| Post vaccination (44/76-SL)N=525,534,273,253 | 99 (98 to 100) | 100 (99 to 100) | 99 (97 to 100) | 2 (0 to 4) |
| Baseline (5/99 strain)N=551,537,280,275 | 4 (2 to 6) | 3 (2 to 5) | 2 (1 to 5) | 4 (2 to 7) |
| Post vaccination (5/99 strain)N=527,529,275,236 | 100 (99 to 100) | 99 (98 to 100) | 100 (99 to 100) | 3 (1 to 7) |
| Baseline(NZ98/254 strain)N=554,543,283,278 | 1 (1 to 3) | 1 (0 to 2) | 1 (0.086 to 3) | 0.1 (0.0091 to 2) |
| Post vaccination(NZ98/254 strain)N=530,534,274,257 | 67 (63 to 71) | 79 (75 to 82) | 69 (63 to 74) | 2 (1 to 5) |
The percentage of subjects with 4-fold rise in hSBA titers at 1 month after 3rd rMenB+OMV NZ vaccination from baseline, when rMenB+OMV NZ was administered concomitantly with routine infant vaccines to when rMenB+OMV NZ vaccine and routine vaccines were given separately.
| Percentages of subjects | B+R246 | B246_R357 | B+R234 | R234 |
|---|---|---|---|---|
| 44/76-SL strain (N=501,507,262,236) | 97 (96 to 99) | 99 (97 to 99) | 98 (96 to 99) | 1 (0 to 4) |
| 5/99 strain (N=497,494,257,217) | 99 (98 to 100) | 99 (98 to 100) | 100 (99 to 100) | 3 (1 to 7) |
| NZ98/254 strain (N=504,503,258,238) | 66 (62 to 70) | 78 (74 to 81) | 69 (63 to 75) | 3 (1 to 5) |
Non-inferiority of immune response to routine vaccine antigens when routine vaccines were administered concomitantly with rMenB+OMV NZ vaccine \[group B+R234\] to when only routine vaccines were given \[Group R234\] were assessed in terms of percentage of subjects achieving seroconversion for pertussis antigens - Filamentous Hemagglutinin (FHA), Pertactin and Pertussis Toxoid (PT) at 1 month after 3rd vaccination versus baseline. Seroconversion was defined as a 4-fold increase for each pertussis antigen or in those initially seropositive, persistence of the pre-vaccination antibody concentration at least at the same antibody concentration as before vaccination, taking into account the decay of maternal antibodies.
| Percentages of subjects | B+R234 | R234 |
|---|---|---|
| FHA | 94 (90 to 97) | 95 (91 to 97) |
| Pertactin | 92 (88 to 95) | 95 (91 to 97) |
| PT | 97 (94 to 99) | 98 (95 to 99) |
Collected over Solicited and unsolicited AEs were collected for 7 days after each vaccination; SAEs, Medically attended AEs and AEs leading to premature withdrawal were collected throughout the study period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| B+R246 | — | 63/625 (10.1%) | 620/625 (99.2%) |
| B246_R357 | — | 57/627 (9.1%) | 623/627 (99.4%) |
| B+R234 | — | 19/318 (6%) | 316/318 (99.4%) |
| R234 | — | 19/312 (6.1%) | 305/312 (97.8%) |
| Event | B+R246 | B246_R357 | B+R234 | R234 |
|---|---|---|---|---|
| GatroenteritisInfections and infestations | 7/625 | 7/627 | 2/318 | 4/312 |
| BronchiolitisInfections and infestations | 2/625 | 3/627 | 2/318 | 3/312 |
| BronchitisInfections and infestations | 4/625 | 6/627 | 2/318 | 2/312 |
| VomitingGastrointestinal disorders | 1/625 | 1/627 | 3/318 | 0/312 |
| PyrexiaGeneral disorders | 5/625 | 4/627 | 1/318 | 1/312 |
| Viral infectionInfections and infestations | 4/625 | 1/627 | 0/318 | 1/312 |
| BronchopneumoniaInfections and infestations | 1/625 | 4/627 | 0/318 | 1/312 |
| PyelonephritisInfections and infestations | 3/625 | 0/627 | 0/318 | 0/312 |
| Urinary tract infectionInfections and infestations | 3/625 | 0/627 | 0/318 | 1/312 |
| ConcussionInjury, poisoning and procedural complications | 3/625 | 0/627 | 1/318 | 0/312 |
| Event | B+R246 | B246_R357 | B+R234 | R234 |
|---|---|---|---|---|
| IrritabilityPsychiatric disorders | 543/625 | 527/627 | 289/318 | 220/312 |
| SomnolenceNervous system disorders | 523/625 | 525/627 | 282/318 | 224/312 |
| Injection Site ErythemaGeneral disorders | 535/625 | 553/627 | 271/318 | 229/312 |
| Injection Site PainGeneral disorders | 544/625 | 536/627 | 279/318 | 182/312 |
| CryingGeneral disorders | 526/625 | 516/627 | 268/318 | 187/312 |
| Injection Site IndurationGeneral disorders | 489/625 | 519/627 | 254/318 | 204/312 |
| PyrexiaGeneral disorders | 514/625 | 462/627 | 246/318 | 176/312 |
| Eating disorderPsychiatric disorders | 470/625 | 473/627 | 249/318 | 159/312 |
| Injection Site SwellingGeneral disorders | 328/625 | 383/627 | 170/318 | 115/312 |
| DiarrheaGastrointestinal disorders | 302/625 | 338/627 | 145/318 | 123/312 |
| Age, Continuous(days) | B+R246 | B246_R357 | B+R234 | R234 | Total |
|---|---|---|---|---|---|
| Mean | 68.7 ± 8.9 | 68.8 ± 9.4 | 68.8 ± 9.1 | 68.1 ± 9.0 | 68.7 ± 9.1 |
| Sex: Female, Male(Participants) | B+R246 | B246_R357 | B+R234 | R234 | Total |
|---|---|---|---|---|---|
| Female | 292 | 312 | 164 | 159 | 927 |
| Male | 335 | 316 | 154 | 153 | 958 |
The record gives a start of Aug 2008, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 4 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 4CMenB vaccine